Cite
Nakano K, Hayakawa K, Funauchi Y, et al. Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line. Mol Clin Oncol. 2020;14(1):13doi: 10.3892/mco.2020.2175.
Nakano, K., Hayakawa, K., Funauchi, Y., Tanizawa, T., Ae, K., Matsumoto, S., Tomomatsu, J., Ono, M., Taira, S., Nishizawa, M., Wang, X., Ohmoto, A., Sato, Y., Fukuda, N., Urasaki, T., & Takahashi, S. (2021). Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line. Molecular and clinical oncology, 14(1), 13. https://doi.org/10.3892/mco.2020.2175
Nakano, Kenji, et al. "Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line." Molecular and clinical oncology vol. 14,1 (2021): 13. doi: https://doi.org/10.3892/mco.2020.2175
Nakano K, Hayakawa K, Funauchi Y, Tanizawa T, Ae K, Matsumoto S, Tomomatsu J, Ono M, Taira S, Nishizawa M, Wang X, Ohmoto A, Sato Y, Fukuda N, Urasaki T, Takahashi S. Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line. Mol Clin Oncol. 2021 Jan;14(1):13. doi: 10.3892/mco.2020.2175. Epub 2020 Nov 25. PMID: 33282288; PMCID: PMC7709564.
Copy
Download .nbib